Bdenza 160mg Tablet

About

Bdenza 160mg Tablet is an androgen receptor inhibitor, primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It works by targeting multiple steps in the androgen receptor signaling pathway, which is crucial for the growth and survival of prostate cancer cells. Bdenza inhibits androgen binding to the androgen receptor, prevents androgen receptor nuclear translocation, and impairs DNA binding and transcription of androgen-responsive genes. This comprehensive blockade of androgen receptor signaling leads to a significant reduction in prostate cancer cell proliferation and induces apoptosis, thereby slowing disease progression.

The medication is administered orally and is extensively metabolized, primarily by CYP2C8 and CYP3A4, with subsequent excretion through both urine and feces. Due to its potent anti-androgenic effects, careful monitoring for potential adverse events, including seizures and cardiovascular issues, is essential. Patients should be educated on the importance of adherence to the prescribed regimen and reporting any new or worsening symptoms to ensure optimal therapeutic outcomes and manage safety concerns effectively.

Uses

• Treatment of metastatic castration-resistant prostate cancer.
• Used in patients who have previously received chemotherapy (e.g., docetaxel).
• Used in patients who are chemotherapy-naive.
• Inhibits androgen receptor signaling in prostate cancer cells.

Directions For Use

Take four 40mg tablets (total 160mg) orally once daily, with or without food. Swallow tablets whole.

Benefits

• Significantly prolongs overall survival in mCRPC.
• Delays disease progression.
• Effective in both pre- and post-chemotherapy settings.
• Oral administration for patient convenience.
• Targets a key pathway in prostate cancer.
• Improves quality of life for patients with advanced prostate cancer.

Side Effects

• Fatigue
• Asthenia (weakness)
• Hot flashes
• Headache
• Hypertension (high blood pressure)
• Nausea
• Diarrhea
• Decreased appetite
• Peripheral edema
• Seizures (rare)
• Falls
• Fractures

Safety Measures

• Alcohol - Alcohol consumption should be limited or avoided during Bdenza treatment, as it may exacerbate central nervous system side effects like dizziness or fatigue, and potentially interact with drug metabolism.
• Pregnancy - Bdenza is not indicated for use in women. It can cause fetal harm. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.
• Breastfeeding - Bdenza is not indicated for use in women. It is unknown if it is excreted in human milk.
• Liver - Patients with severe hepatic impairment may require dose adjustments for Bdenza, as it is extensively metabolized in the liver. Close monitoring of liver function is recommended.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment. However, caution is advised in severe renal impairment, and monitoring for adverse effects is important.
• Lung - While not directly affecting lung function, patients should be monitored for any new or worsening respiratory symptoms, as general adverse events can sometimes manifest broadly. No specific lung contraindication.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.